204 related articles for article (PubMed ID: 17456722)
1. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
Flotho C; Coustan-Smith E; Pei D; Cheng C; Song G; Pui CH; Downing JR; Campana D
Blood; 2007 Aug; 110(4):1271-7. PubMed ID: 17456722
[TBL] [Abstract][Full Text] [Related]
2. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
Flotho C; Coustan-Smith E; Pei D; Iwamoto S; Song G; Cheng C; Pui CH; Downing JR; Campana D
Blood; 2006 Aug; 108(3):1050-7. PubMed ID: 16627760
[TBL] [Abstract][Full Text] [Related]
3. Predicting outcome in childhood acute lymphoblastic leukemia using gene expression profiling: prognostication or protocol selection?
Catchpoole D; Guo D; Jiang H; Biesheuvel C
Blood; 2008 Feb; 111(4):2486-7; author reply 2487-8. PubMed ID: 18263786
[No Abstract] [Full Text] [Related]
4. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
6. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
8. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
10. Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.
Stanulla M; Schrauder A
Haematologica; 2009 Jun; 94(6):748-52. PubMed ID: 19483150
[No Abstract] [Full Text] [Related]
11. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
12. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.
Choi J; Hwang YK; Sung KW; Lee SH; Yoo KH; Jung HL; Koo HH; Kim HJ; Kang HJ; Shin HY; Ahn HS
Blood; 2007 Jan; 109(2):471-7. PubMed ID: 16990595
[TBL] [Abstract][Full Text] [Related]
13. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
14. Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.
Fedasenka UU; Shman TV; Savitski VP; Belevcev MV
Exp Oncol; 2008 Sep; 30(3):248-52. PubMed ID: 18806751
[TBL] [Abstract][Full Text] [Related]
15. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
[TBL] [Abstract][Full Text] [Related]
17. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
[TBL] [Abstract][Full Text] [Related]
19. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
Stow P; Key L; Chen X; Pan Q; Neale GA; Coustan-Smith E; Mullighan CG; Zhou Y; Pui CH; Campana D
Blood; 2010 Jun; 115(23):4657-63. PubMed ID: 20304809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
